Propylene Glycol

Propylene Glycol

SCHEMBL1472372

CC(O)CO.O=C(O)CCCCC(=O)OCCO

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Propylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.45
DGKA P23743 2/20 0.43
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
DUSP3 P51452 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
MGLL Q99685 1/20 0.42
TSHR P16473 1/20 0.41
GPR84 Q9NQS5 1/20 0.41
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
ALDH1A1 P00352 1/20 0.40
PAM P19021 2/20 0.40
CAMK2A Q9UQM7 1/20 0.39
PRKCA P17252 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCQ Q04759 1/20 0.37
PRKCD Q05655 1/20 0.37
ADRA2A P08913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15345844 0.90 DGKA (0.43) MAPTDGKALMNAKDM4EDUSP3
SCHEMBL26442 0.87 GPR84 (0.52) DGKALMNAMGLLTSHRGPR84
SCHEMBL2955658 0.86 DGKA (0.43) MAPTDGKALMNAKDM4EDUSP3
Adipic Acid SCHEMBL28895995 0.85 TSHR (0.50) DGKALMNAMGLLTSHRGPR84
Ammonia Solution, Strong SCHEMBL7134656 0.85 GPR84 (0.50) DGKALMNAMGLLTSHRGPR84
SCHEMBL4159638 0.85 GPR84 (0.56) DGKALMNAMEN1KMT2AMGLL
Water SCHEMBL11810660 0.85 GPR84 (0.50) DGKALMNAMGLLTSHRGPR84
SCHEMBL176409 0.85 GPR84 (0.56) DGKALMNAMEN1KMT2AMGLL
Ethylene Glycol SCHEMBL4909367 0.85 GPR84 (0.50) DGKALMNAMGLLTSHRGPR84
SCHEMBL729520 0.85 GPR84 (0.56) DGKALMNAMEN1KMT2AMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971427-A1 VISIBLE LIGHT CURING SYSTEMS, METHODS FOR REDUCING HEALTH RISKS TO INDIVIDUALS EXPOSED TO SYSTEMS DESIGNED TO CURE CURABLE COMPOSITIONS BY EXPOSURE TO RADIATION, METHODS FOR BONDING SUBSTRATES AND VISIBLE LIGHT CURING COMPOSITIONS Henkel Corporation (US) 2008-09-24 EP claimed
WO-2007078851-A1 VISIBLE LIGHT CURING SYSTEMS, METHODS FOR REDUCING HEALTH RISKS TO INDIVIDUALS EXPOSED TO SYSTEMS DESIGNED TO CURE CURABLE COMPOSITIONS BY EXPOSURE TO RADIATION, METHODS FOR BONDING SUBSTRATES AND VISIBLE LIGHT CURING COMPOSITIONS HENKEL CORPORATION (US) 2007-07-12 WO claimed
US-20070138411-A1 Visible light curing systems, methods for reducing health risks to individuals exposed to systems designed to cure curable compositions by exposure to radiation, methods for bonding substrates and visible light curing compositions HENKEL CORPORATION 2007-06-21 US claimed
WO-2006083343-A1 VINYL ETHER/ACRYLATE BLOCK RESINS, COMPOSITIONS AND METHODS OF MAKING SAME HENKEL CORPORATION (US) 2006-08-10 WO claimed
CN-112824978-A Cleaning blade, process cartridge, and image forming apparatus 株式会社理光 2021-05-21 CN disclosed
US-9994690-B2 Cellular porous monoliths containing condensed tannins UNIVERSITE DE LORRAINE (FR) 2018-06-12 US disclosed
EP-2890555-B1 CELLULAR POROUS MONOLITHS CONTAINING CONDENSED TANNINS UNIV LORRAINE (FR) 2016-09-28 EP disclosed
US-20150274921-A1 CELLULAR POROUS MONOLITHS CONTAINING CONDENSED TANNINS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-10-01 US disclosed
EP-2890555-A1 CELLULAR POROUS MONOLITHS CONTAINING CONDENSED TANNINS Université de Lorraine (FR) 2015-07-08 EP disclosed
WO-2014033124-A1 CELLULAR POROUS MONOLITHS CONTAINING CONDENSED TANNINS UNIVERSITE DE LORRAINE (FR) 2014-03-06 WO disclosed
US-7915319-B2 Visible light curing systems, methods for reducing health risks to individuals exposed to systems designed to cure curable compositions by exposure to radiation, methods for bonding substrates and visible light curing compositions HENKEL CORPORATION (US) 2011-03-29 US disclosed
EP-1971427-A1 VISIBLE LIGHT CURING SYSTEMS, METHODS FOR REDUCING HEALTH RISKS TO INDIVIDUALS EXPOSED TO SYSTEMS DESIGNED TO CURE CURABLE COMPOSITIONS BY EXPOSURE TO RADIATION, METHODS FOR BONDING SUBSTRATES AND VISIBLE LIGHT CURING COMPOSITIONS Henkel Corporation (US) 2008-09-24 EP disclosed
US-20080139687-A1 Vinyl Ether/Acrylate Block Resins, Compositions and Methods of Making Same HENKEL CORPORATION (US) 2008-06-12 US disclosed
WO-2007078851-A1 VISIBLE LIGHT CURING SYSTEMS, METHODS FOR REDUCING HEALTH RISKS TO INDIVIDUALS EXPOSED TO SYSTEMS DESIGNED TO CURE CURABLE COMPOSITIONS BY EXPOSURE TO RADIATION, METHODS FOR BONDING SUBSTRATES AND VISIBLE LIGHT CURING COMPOSITIONS HENKEL CORPORATION (US) 2007-07-12 WO disclosed
US-20070138411-A1 Visible light curing systems, methods for reducing health risks to individuals exposed to systems designed to cure curable compositions by exposure to radiation, methods for bonding substrates and visible light curing compositions HENKEL CORPORATION 2007-06-21 US disclosed
WO-2006083343-A1 VINYL ETHER/ACRYLATE BLOCK RESINS, COMPOSITIONS AND METHODS OF MAKING SAME HENKEL CORPORATION (US) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274921-A1 CELLULAR POROUS MONOLITHS CONTAINING CONDENSED TANNINS HES1, PITRM1, TAS2R46 MAPT 2753/4885DGKA 2840/4885LMNA 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.